LAM
SUPN icon

Lebenthal Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Lebenthal Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-345
Closed -$9K – 635
2016
Q3 		$9K Buy
+345
New +$7.81K ﹤0.01% 777

Other funds holding SUPN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Lebenthal Asset Management's SUPN Position: Q4 2016 in Review

Lebenthal Asset Management sold out of Supernus Pharmaceuticals (SUPN) in Q4 2016, closing a stake of 345 shares — an estimated $9K sold.

Lebenthal Asset Management first reported a position in SUPN in Q3 2016 and held it in 1 quarter. The position peaked at $9K in Q3 2016. 234 funds tracked by Wall St. Rank hold SUPN as of Q4 2016.

  • Lebenthal Asset Management reported no remaining Supernus Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Lebenthal Asset Management sold 345 Supernus Pharmaceuticals shares in Q4 2016, an estimated $9K.
  • Lebenthal Asset Management first reported a position in Supernus Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • Lebenthal Asset Management's Supernus Pharmaceuticals position peaked at $9K in Q3 2016.
  • 234 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2016.

Based on Lebenthal Asset Management's 13F filing for Q4 2016, filed 15 Feb 2017.